The international biotech sector clocked in at $1.37 trillion in 2022 despite headwinds such as slow launches, long-term drug pricing shifts and changing consumer behavior. Recent biotech breakthroughs include the development of an Ebola vaccine, progress in genetic testing and drug treatments and advances in artificial tissue growth. This article explores several leading biotech…
Seven biologics walking the approval tightrope in 2023
As we venture into the second half of 2023, the global biologics market continues to hover between robust growth and unpredictability. Valued at $461.74 billion in 2022, it’s projected to grow at a compound annual rate of 10.3% from 2023 to 2030, according to Grand View Research. In 2022, biologics edged past small molecules for…